Journal
BREAST
Volume 16, Issue 3, Pages 235-240Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2007.02.006
Keywords
intrinsic gene set; molecular classification; ErbB2; neoadjuvant chemotherapy; breast cancer
Categories
Ask authors/readers for more resources
Gene expression profiting using Affymetrix HG-U133 Arrays (22,500 genes) was performed on fresh frozen pretherapeutic core biopsies from 50 patients undergoing neoadjuvant chemotherapy (NAC) with docetaxel, adriamycin, cyclophosphamide (TAC) within the GEPARTRIO trial. The Sortie classification based on the intrinsic gene set revealed four different subgroups in our cohort (normal-like: 14%, basal-like: 20%, erbB2+: 22% and luminal: 44%), which is in tine with the original description. High genomic grade but not histopathological grading was statistically different within the four subgroups (P < 0.001). About 45.5% of tumors classified according to erbB2+ cluster showed a pathological complete response compared to 0% in the normal-like, 10.0% in the basal-like and 9.1% in the luminal. subgroup (P = 0.024). There was a trend to less tumor relapses in the erbB2+ subgroup (0%) compared to the normal-like (28.6%), basal-like (30.0%) and luminal (13.6%) cluster (P = 0.215). Our data suggest that the molecular tumor subtypes based on the intrinsic gene set can be used to predict tumor response according to NAC. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available